Megan Stark
BSc (Physics), MSc
This person is no longer at the institute and this page is for historical access to their publications only
Publications
Provided on request for non-commercial personal use by researchers.
2024
Aye, W. W., Stark, M. R., Horne, K.-L., Livingston, L., Grenfell, S., Myall, D. J., Pitcher, T.L., Almuqbel, M.M., Keenan, R. J., Meissner, W.G., Dalrymple-Alford, J., Anderson, T.J., Le Heron, C., Melzer, T. R. (2024). Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 16(2),
e12601..
10.1002/dad2.12601
2019
Melzer, T. R., Stark, M. R., Keenan, R. J., Myall, D. J., MacAskill, M. R., Pitcher, T. L., Livingston, L., Grenfell, S., Horne, K., Young, B., Pascoe, M., Almuqbel, M. A., Wang, J., Marsh, S., Miller, D. H., Dalrymple-Alford, J. C., Anderson, T. J. (2019). Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Frontiers in Neurology,
10, .
10.3389/fneur.2019.00391
_2024.pdf.jpeg)
